<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380717</url>
  </required_header>
  <id_info>
    <org_study_id>RenVas</org_study_id>
    <nct_id>NCT01380717</nct_id>
  </id_info>
  <brief_title>Renal and Systemic Vascular Resistance in Chronic Kidney Disease (CKD)</brief_title>
  <acronym>RenVas</acronym>
  <official_title>The Role of Renal and Peripheral Vascular Resistance in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with reduced kidney function have a higher risk of heart disease and death. Studies
      have shown that blood vessels in patients with hypertension change with a decrease of lumen
      size and growth of the vessel wall. By treating patients with antihypertensive certain
      medication vessel lumen and walls normalize. Treating hypertension in patients with chronic
      kidney disease slows the progression of kidney function loss.

      The aim is to compare different degrees of antihypertensive medication in patients with
      chronic kidney disease and hypertension will slow the progression of kidney loss.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glomerular filtration rate between the two treatment arms.</measure>
    <time_frame>Measured at baseline and after 18 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in glomerular filtration rate stratified after changes in pulse wave velocity, renal vascular resistance and forearm minimal resistance at baseline and after 18 months of treatment.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Chronic Kidney Insufficiency</condition>
  <condition>Hypertension</condition>
  <condition>Vasodilation</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with CKD 3-4, hypertension, treated for 18 months with beta-blocker and if needed ACE-inhibitor or ARB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive vasodilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with CKD 3-4 and hypertension, randomized to treatment with calcium channel blocker and if needed ACE-inhibitor or ARB for 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta-blocker, ACE-inhibitor</intervention_name>
    <description>Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day</description>
    <arm_group_label>Standard treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Channel Blockers, ACE-Inhibitor</intervention_name>
    <description>Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day</description>
    <arm_group_label>Intensive vasodilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  eGFR 15-60 ml/min for at least 3 months

          -  Blood pressure &gt; 130 mmHg systolic og &gt;80 mmHg diastolic (patients without
             antihypertensive treatment or in treatment with Beta-blockers, ACEi, ARBs or CCB not
             in maximum dosi).

          -  Blood pressure &lt; 130 mmHg systolic og &lt; 80 mmHg diastolic (patients receiving
             Beta-blockers, ACEi, ARBs og CCB).

          -  Fertile women using safe contraceptives

        Exclusion Criteria:

          -  Ultrasound verified Polycystic Kidney Disease (ADPKD)

          -  Claustrophobia (MRi scan).

          -  Contraindications to MRi.

          -  Pregnancy or wish to become pregnant in the study period.

          -  Nephrotic syndrome with gross edema.

          -  Known allergy to any study medication.

          -  Blood pressure &lt; 130 mmHg systolic or &lt; 80 mmHg diastolic without antihypertensive
             treatment.

          -  Blood pressure &gt; 130 mmHg systolic or &gt; 80 mmHg diastolic and in maximum dosages of
             all three Beta-blockers, ACEi (ARBs) and CCB.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Henrik Buus, DrMedSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department og Renal Medicine, Aarhus University Hospital, Skejby</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Renal Medicine, Aarhus University Hospital, Skejby</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>February 26, 2014</last_update_submitted>
  <last_update_submitted_qc>February 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

